Clinical course of untreated cerebral cavernous malformations: a meta-analysis of individual patient data

Margaret A Horne, Kelly D Flemming, I-Chang Su, Christian Stapf, Jin Pyeong Jeon, Da Li, Susanne S Maxwell, Philip White, Teresa J Christianson, Ronit Agid, Won-Sang Cho, Chang Wan Oh, Zhen Wu, Jun-Ting Zhang, Jeong Eun Kim, Karel Ter Brugge, Robert Willinsky, Robert D Brown Jr, Gordon D Murray, Rustam Al-Shahi Salman, Cerebral Cavernous Malformations Individual Patient Data Meta-analysis Collaborators, Margaret A Horne, Kelly D Flemming, I-Chang Su, Christian Stapf, Jin Pyeong Jeon, Da Li, Susanne S Maxwell, Philip White, Teresa J Christianson, Ronit Agid, Won-Sang Cho, Chang Wan Oh, Zhen Wu, Jun-Ting Zhang, Jeong Eun Kim, Karel Ter Brugge, Robert Willinsky, Robert D Brown Jr, Gordon D Murray, Rustam Al-Shahi Salman, Cerebral Cavernous Malformations Individual Patient Data Meta-analysis Collaborators

Abstract

Background: Cerebral cavernous malformations (CCMs) can cause symptomatic intracranial haemorrhage (ICH), but the estimated risks are imprecise and predictors remain uncertain. We aimed to obtain precise estimates and predictors of the risk of ICH during untreated follow-up in an individual patient data meta-analysis.

Methods: We invited investigators of published cohorts of people aged at least 16 years, identified by a systematic review of Ovid MEDLINE and Embase from inception to April 30, 2015, to provide individual patient data on clinical course from CCM diagnosis until first CCM treatment or last available follow-up. We used survival analysis to estimate the 5-year risk of symptomatic ICH due to CCMs (primary outcome), multivariable Cox regression to identify baseline predictors of outcome, and random-effects models to pool estimates in a meta-analysis.

Findings: Among 1620 people in seven cohorts from six studies, 204 experienced ICH during 5197 person-years of follow-up (Kaplan-Meier estimated 5-year risk 15·8%, 95% CI 13·7-17·9). The primary outcome of ICH within 5 years of CCM diagnosis was associated with clinical presentation with ICH or new focal neurological deficit (FND) without brain imaging evidence of recent haemorrhage versus other modes of presentation (hazard ratio 5·6, 95% CI 3·2-9·7) and with brainstem CCM location versus other locations (4·4, 2·3-8·6), but age, sex, and CCM multiplicity did not add independent prognostic information. The 5-year estimated risk of ICH during untreated follow-up was 3·8% (95% CI 2·1-5·5) for 718 people with non-brainstem CCM presenting without ICH or FND, 8·0% (0·1-15·9) for 80 people with brainstem CCM presenting without ICH or FND, 18·4% (13·3-23·5) for 327 people with non-brainstem CCM presenting with ICH or FND, and 30·8% (26·3-35·2) for 495 people with brainstem CCM presenting with ICH or FND.

Interpretation: Mode of clinical presentation and CCM location are independently associated with ICH within 5 years of CCM diagnosis. These findings can inform decisions about CCM treatment.

Funding: UK Medical Research Council, Chief Scientist Office of the Scottish Government, and UK Stroke Association.

Copyright © 2016 Horne et al. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd.. All rights reserved.

Figures

Figure 1
Figure 1
Study flowchart CCM=cerebral cavernous malformation. *See appendix pp 18–19. †See appendix pp 19–20 for references. ‡One eligible study provided data from two time periods, which are included as two separate cohorts. §See appendix p 20.
Figure 2
Figure 2
Forest plots of associations between mode of presentation and cerebral cavernous malformation location with primary and secondary outcomes Plots show cohort-level and pooled estimates of associations between ICH or FND at presentation (A and C) or brainstem CCM location (B and D) and outcome during 5 years of follow-up. The area of each shaded box is proportional to the weight of the cohort it represents. CCM=cerebral cavernous malformation. FND=focal neurological deficit. HR=hazard ratio. ICH=intracranial haemorrhage.
Figure 3
Figure 3
Kaplan-Meier plots of progression to intracranial haemorrhage or to intracranial haemorrhage or focal neurological deficit Plots show the proportion of people progressing to ICH (A) or ICH or FND (B) during follow-up, stratified by ICH or FND presentation from brainstem CCMs, ICH or FND presentation from non-brainstem CCMs, other presentation from brainstem CCMs, and other presentation from non-brainstem CCMs. CCM=cerebral cavernous malformation. FND=focal neurological deficit. HR=hazard ratio. ICH=intracranial haemorrhage.

References

    1. Greving JP, Wermer MJH, Brown RD., Jr Development of the PHASES score for prediction of risk of rupture of intracranial aneurysms: a pooled analysis of six prospective cohort studies. Lancet Neurol. 2014;13:59–66.
    1. Morris Z, Whiteley WN, Longstreth WT., Jr Incidental findings on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2009;339:b3016.
    1. Vernooij MW, Ikram MA, Tanghe HL. Incidental findings on brain MRI in the general population. N Engl J Med. 2007;357:1821–1828.
    1. Rigamonti D, Drayer BP, Johnson PC, Hadley MN, Zabramski J, Spetzler RF. The MRI appearance of cavernous malformations (angiomas) J Neurosurg. 1987;67:518–524.
    1. Brown RD, Wiebers DO, Torner JC, O'Fallon WM. Frequency of intracranial hemorrhage as a presenting symptom and subtype analysis: a population-based study of intracranial vascular malformations in Olmsted County, Minnesota. J Neurosurg. 1996;85:29–32.
    1. Al-Shahi R, Bhattacharya JJ, Currie DG. Prospective, population-based detection of intracranial vascular malformations in adults: the Scottish Intracranial Vascular Malformation Study (SIVMS) Stroke. 2003;34:1163–1169.
    1. Rosenow F, Alonso-Vanegas MA, Baumgartner C. Cavernoma-related epilepsy: review and recommendations for management—report of the Surgical Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2013;54:2025–2035.
    1. Al-Shahi Salman R, Berg MJ, Morrison L, Awad IA, on behalf of the Angioma Alliance Scientific Advisory B Hemorrhage from cavernous malformations of the brain: definition and reporting standards. Stroke. 2008;39:3222–3230.
    1. Lauer MS. Elements of danger—the case of medical imaging. N Engl J Med. 2009;361:841–843.
    1. Poorthuis MHF, Klijn CJM, Algra A, Rinkel GJE, Al-Shahi Salman R. Treatment of cerebral cavernous malformations: a systematic review and meta-regression analysis. J Neurol Neurosurg Psychiatry. 2014;85:1319–1323.
    1. Al-Shahi Salman R, Hall JM, Horne MA. Untreated clinical course of cerebral cavernous malformations: a prospective, population-based cohort study. Lancet Neurol. 2012;11:217–224.
    1. Riley RD, Hayden JA, Steyerberg EW. Prognosis Research Strategy (PROGRESS) 2: prognostic factor research. PLoS Med. 2013;10:1–9.
    1. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. Br Med J. 2010;340:c221.
    1. Great Ormond Street Hospital for Children Transition to adult services. (accessed Nov 23, 2015).
    1. NHS Health Research Authority Confidentiality Advisory Group (CAG) – Determining the need for a CAG application. (accessed Nov 23, 2015).
    1. Cochrane Methods Bias Tool to assess risk of bias in cohort studies. (accessed Nov 23, 2015).
    1. Porter PJ, Willinsky RA, Harper W, Wallace MC. Cerebral cavernous malformations: natural history and prognosis after clinical deterioration with or without hemorrhage. J Neurosurg. 1997;87:190–197.
    1. Flemming KD, Link MJ, Christianson TJH, Brown RD., Jr Prospective hemorrhage risk of intracerebral cavernous malformations. Neurology. 2012;78:632–636.
    1. Jeon J, Kim J, Chung Y. A risk factor analysis of prospective symptomatic haemorrhage in adult patients with cerebral cavernous malformation. J Neurol Neurosurg Psychiatry. 2014;85:1366–1370.
    1. Li D, Hao S-Y, Jia G-J, Wu Z, Zhang L-W, Zhang J-T. Hemorrhage risks and functional outcomes of untreated brainstem cavernous malformations. J Neurosurg. 2014;121:32–41.
    1. Lewis S. Regression analysis. Pract Neurol. 2007;7:259–264.
    1. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med. 2006;25:127–141.
    1. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361–387.
    1. Borenstein M, Hedges L, Higgins J, Rothstein H. Introduction to meta-analysis. John Wiley; Chichester, UK: 2009.
    1. Riley RD, Higgins JPT, Deeks JJ. Interpretation of random effects meta-analyses. Br Med J. 2011;342:964–967.
    1. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558.
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J. 2003;327:557–560.
    1. Machin D, Cheung YB, Parmar MKB. Survival analysis: a practical approach. 2nd ed. John Wiley; Chichester, UK: 2006.
    1. Steyerberg EW. Clinical prediction models. Springer; New York: 2009.
    1. Schneble HM, Soumare A, Herve D. Antithrombotic therapy and bleeding risk in a prospective cohort study of patients with cerebral cavernous malformations. Stroke. 2012;43:3196–3199.
    1. Clark TG, Altman DG, De Stavola BL. Quantification of the completeness of follow-up. Lancet. 2002;359:1309–1310.
    1. Moultrie F, Horne MA, Josephson CB. Outcome after surgical or conservative management of cerebral cavernous malformations. Neurology. 2014;83:1–8.

Source: PubMed

3
Subskrybuj